Metabolomics in cancer: A bench-to-bedside intersection

Critical Reviews in Oncology/Hematology

Volumn 84, Issue 1, 2012, Pages 1-7

  Claudino, Wederson M ^a   Goncalves, Priscila H ^a   di Leo, Angelo ^b   Philip, Philip A ^a   Sarkar, Fazlul H ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ISTITUTO TOSCANO TUMORI   (Italy)

Author keywords

Biology; Cancer; Metabolomics

Indexed keywords

BETAINE; CISPLATIN; PARACETAMOL; PHOSPHATIDYLINOSITOL 3 KINASE; TAURINE; TRIMETHYLAMINE OXIDE;

BREAST CANCER; CANCER GRADING; CANCER PROGNOSIS; CANCER RESEARCH; CANCER SCREENING; CANCER STAGING; EARLY DIAGNOSIS; HUMAN; LIQUID CHROMATOGRAPHY; LIVER TOXICITY; MASS FRAGMENTOGRAPHY; MASS SPECTROMETRY; METABOLOMICS; NEPHROTOXICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OLIGODENDROGLIOMA; PARTIAL LEAST SQUARES REGRESSION; PREDICTIVE VALUE; PRINCIPAL COMPONENT ANALYSIS; REVIEW; TUMOR CLASSIFICATION;

EID: 84866488967     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2012.02.009     Document Type: Review

References (30)

1. Dettmer K., Hammock B.D. Metabolomics-a new exciting field within the omics sciences. Environ Health Perspect 2004, 112:A396-A397.
2. Griffin J.L. Metabolic profiles to define the genome: can we hear the phenotypes?. Philos Trans R Soc Lond B Biol Sci 2004, 359:857-871.
3. Borgan E., Sitter B., Lingjaerde O.C., et al. Merging transcriptomics and metabolomics-advances in breast cancer profiling. BMC Cancer 2010, 10:628.
4. Cavill R., Kamburov A., Ellis J.K., et al. Consensus-phenotype integration of transcriptomic and metabolomic data implies a role for metabolism in the chemosensitivity of tumour cells. PLoS Comput Biol 2011, 7:pe1001113.
5. Robertson D.G., Watkins P.B., Reily M.D. Metabolomics in toxicology: preclinical and clinical applications. Toxicol Sci 2011, 120(Suppl. 1):S146-S170.
6. Fossel E.T., Carr J.M., McDonagh J. Detection of malignant tumors. Water-suppressed proton nuclear magnetic resonance spectroscopy of plasma. N Engl J Med 1986, 315:1369-1376.
7. Kroemer G., Pouyssegur J. Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 2008, 13:472-482.
8. Griffin J.L., Shockcor J.P. Metabolic profiles of cancer cells. Nat Rev Cancer 2004, 4(2004):551-561.
9. Malet-Martino M., Holzgrabe U. NMR techniques in biomedical and pharmaceutical analysis. J Pharm Biomed Anal 2011, 55:1-15.
10. Claudino W.M., Quattrone A., Biganzoli L., Pestrin M., Bertini I., Di L.A. Metabolomics: available results, current research projects in breast cancer, and future applications. J Clin Oncol 2007, 25:2840-2846.
11. Keun H.C., Athersuch T.J. Nuclear magnetic resonance (NMR)-based metabolomics. Methods Mol Biol 2011, 708:321-334.
12. Van Q.N., Veenstra T.D. How close is the bench to the bedside? Metabolic profiling in cancer research. Genome Med 2009, 1-6.
13. Kouskoumvekaki I., Panagiotou G. Navigating the human metabolome for biomarker identification and design of pharmaceutical molecules. J Biomed Biotechnol 2011, 2011. pii:525497.
14. Sreekumar A., Poisson L.M., Rajendiran T.M., et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 2009, 457:910-914.
15. 1H NMR spectroscopy and principal component analysis. Appl Biochem Biotechnol 2011, 165:148-154.
16. Slupsky C.M., Steed H., Wells T.H., et al. Urine metabolite analysis offers potential early diagnosis of ovarian and breast cancers. Clin Cancer Res 2010, 16:5835-5841.
17. Wu H., Xue R., Tang Z., et al. Metabolomic investigation of gastric cancer tissue using gas chromatography/mass spectrometry. Anal Bioanal Chem 2010, 396:1385-1395.
18. Lin L., Huang Z., Gao Y., Yan X., Xing J., Hang W. LC-MS based serum metabonomic analysis for renal cell carcinoma diagnosis, staging, and biomarker discovery. J Proteome Res 2011, 10:1396-1405.
19. Putluri N., Shojaie A., Vasu V.T., et al. Metabolomic profiling reveals potential markers and bioprocessors altered in bladder cancer progression. Cancer Res 2011, 71:7376-7386.
20. Erb G., Elbayed K., Piotto M., et al. Toward improved grading of malignancy in oligodendrogliomas using metabolomics. Magn Reson Med 2008, 59:959-965.
21. Fox E., Curt G.A., Balis F.M. Clinical trial design for target-based therapy. Oncologist 2002, 7:401-409.
22. Al-Saffar N.M., Jackson L.E., Raynaud F.I., et al. The phosphoinositide 3-kinase inhibitor PI-103 downregulates choline kinase alpha leading to phosphocholine and total choline decrease detected by magnetic resonance spectroscopy. Cancer Res 2010, 70:5507-5517.
23. Clinicaltrials.goc [accessed 24.07.11].
24. Beloueche-Babari M., Jackson L.E., Al-Saffar N.M., Workman P., Leach M.O., Ronen S.M. Magnetic resonance spectroscopy monitoring of mitogen-activated protein kinase signaling inhibition. Cancer Res 2005, 65:3356-3363.
25. Boros L.G., Brackett D.J., Harrigan G.G. Metabolic biomarker and kinase drug target discovery in cancer using stable isotope-based dynamic metabolic profiling (SIDMAP). Curr Cancer Drug Targets 2003, 3:445-453.
26. Nicholson J.K., Wilson I.D., Lindon J.C. Pharmacometabonomics as an effector for personalized medicine. Pharmacogenomics 2011, 12:103-111.
27. Ebbels T.M., Keun H.C., Beckonert O.P., et al. Prediction and classification of drug toxicity using probabilistic modeling of temporal metabolic data: the consortium on metabonomic toxicology screening approach. J Proteome Res 2007, 6:4407-4422.
28. Kwon H.N., Kim M., Wen H., et al. Predicting idiopathic toxicity of cisplatin by a pharmacometabonomic approach. Kidney Int 2011, 79:529-537.
29. Clayton T.A., Lindon J.C., Cloarec O., et al. Pharmaco-metabonomic phenothyping and personalized drug treatment. Nature 2006, 440:1073-1077.
30. Lindon J.C., Nicholson J.K., Holmes E., et al. Standard Metabolic Reporting Structures working group. Summary recommendations for standardization and reporting of metabolic analyses. Nat Biotechnol 2005, 23:833-838.